Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Conconi, Annarita; Zucca, Emanuele; Margiotta-Casaluci, Gloria; Darling, Katharine; Hasse, Barbara; Battegay, Manuel; Staehelin, Cornelia; Novak, Urban; Schmid, Patrick; Scherrer, Alexandra; Dirnhofer, Stephan; Kwee, Ivo; Nassi, Luca; Cavalli, Franco; Gaidano, Gianluca; Bertoni, Francesco; Bernasconi, Enos (2018). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematological oncology, 36(5), pp. 757-764. Wiley 10.1002/hon.2536

[img] Text
Conconi_et_al-2018-Hematological_Oncology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (307kB) | Request a copy

The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). The acquired immunodeficiency syndrome-related lymphoma international prognostic index predicted OS in AR-DLBCL. Among 148 patients younger than 61 years (40 AR-DLBCL and 108 IC-DLBCL) treated with RCHOP/RCHOP-like regimens, 20 IC-DLBCL and 9 AR-DLBCL patients died and OS was not significantly different. A higher proportion of early deaths occurred in the AR-DLBCL: indeed, 1-year OS was 94% (95% CI: 87%-97%) in IC-DLBCL and 82% (95% CI: 66%-91%) in AR-DLBCL patients. After rituximab and active antiretroviral therapy introduction, AR-DLBCL and IC-DLBCL patients treated with curative intent have similar long-term survival.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Staehelin, Cornelia and Novak, Urban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1099-1069

Publisher:

Wiley

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

29 Aug 2018 09:50

Last Modified:

23 Oct 2019 06:19

Publisher DOI:

10.1002/hon.2536

PubMed ID:

30113708

Uncontrolled Keywords:

AIDS HIV infection diffuse large B-cell lymphoma prognostic factors therapy

BORIS DOI:

10.7892/boris.119432

URI:

https://boris.unibe.ch/id/eprint/119432

Actions (login required)

Edit item Edit item
Provide Feedback